{"hands_on_practices": [{"introduction": "In clinical practice, differentiating between acute generalized desquamating diseases in children, such as Staphylococcal Scalded Skin Syndrome (SSSS) and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN), is a critical and time-sensitive challenge. This exercise [@problem_id:5208405] allows you to practice using a key clinical finding—the sparing of mucosal surfaces—to systematically update your diagnostic certainty. By applying Bayes' theorem, you will quantitatively see how a single, carefully observed physical sign can dramatically increase the post-test probability of SSSS, transforming clinical intuition into a robust, evidence-based assessment.", "problem": "A $3$-year-old previously healthy child presents with $2$ days of fever, irritability, and a rapidly progressive, tender, diffuse erythematous rash with flaccid bullae and sheet-like desquamation. The Nikolsky sign is positive over the trunk and flexures. On close inspection, the oral cavity, bulbar and palpebral conjunctivae, and genital mucosa are all intact without erosions. There are perioral fissures and crusting, but no intraoral lesions. You consider staphylococcal scalded skin syndrome (SSSS) versus Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) as the leading diagnoses.\n\nIn your emergency department population, among children with acute generalized desquamation, the pre-test probability of SSSS is estimated at $40\\%$, with most of the remainder being SJS/TEN. From high-quality pediatric studies, the probability that all oral, ocular, and genital mucosa are intact given SSSS is approximately $0.95$, while the probability that all of these mucosa are intact given SJS/TEN is approximately $0.05$.\n\nBased solely on these data and accepted principles of probabilistic clinical reasoning, which of the following best estimates the post-test probability that this child has SSSS after observing intact oral, ocular, and genital mucosa, and provides the most accurate pathophysiologic explanation for why this clinical observation discriminates SSSS from SJS/TEN?\n\nA. Approximately $80\\%$; SSSS causes full-thickness epidermal necrosis, but mucosa are relatively resistant, explaining mucosal sparing.\n\nB. Approximately $93\\%$; Staphylococcus aureus exfoliative toxin cleaves desmoglein $1$ within the superficial epidermis, sparing mucosa where desmoglein $3$ predominates.\n\nC. Approximately $65\\%$; the desquamation in SSSS is due to localized bullous impetigo, which does not affect mucosa.\n\nD. Approximately $99\\%$; SSSS is driven by immune-mediated keratinocyte apoptosis targeting mucosal epithelia less than keratinized epidermis.", "solution": "The problem statement is evaluated for validity before proceeding to a solution.\n\n### Step 1: Extract Givens\n- Patient presentation: A $3$-year-old previously healthy child with a $2$-day history of fever, irritability, and a rapidly progressive, tender, diffuse erythematous rash with flaccid bullae and sheet-like desquamation.\n- Physical finding: Positive Nikolsky sign.\n- Key observation ($M$): Oral, ocular, and genital mucosa are all intact without erosions.\n- Differential diagnoses: Staphylococcal scalded skin syndrome (SSSS) and Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN).\n- Pre-test probability of SSSS: $P(\\text{SSSS}) = 40\\% = 0.40$.\n- Pre-test probability of SJS/TEN: Since SJS/TEN constitutes \"most of the remainder,\" we can infer $P(\\text{SJS/TEN}) = 1 - P(\\text{SSSS}) = 1 - 0.40 = 0.60$.\n- Conditional probability of intact mucosa given SSSS: $P(M | \\text{SSSS}) = 0.95$.\n- Conditional probability of intact mucosa given SJS/TEN: $P(M | \\text{SJS/TEN}) = 0.05$.\n- The task is to calculate the post-test probability of SSSS given the observation of intact mucosa, $P(\\text{SSSS} | M)$, and to identify the correct pathophysiologic explanation for this finding.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientifically Grounded**: The problem is grounded in established principles of pediatrics, dermatology, and clinical epidemiology. The clinical presentation is a classic scenario for discriminating between SSSS and SJS/TEN. The distinction based on mucosal involvement is a critical and well-documented clinical sign. The pathophysiological mechanisms for SSSS (exfoliative toxin cleavage of desmoglein-1) and SJS/TEN (immune-mediated keratinocyte apoptosis) are scientifically well-established. The provided probabilities are reasonable for a clinical context.\n- **Well-Posed**: The problem is well-posed. It requests the calculation of a post-test probability using Bayesian inference. All necessary components for Bayes' theorem—prior probabilities and conditional probabilities (likelihoods)—are explicitly provided. This allows for the calculation of a unique, meaningful solution.\n- **Objective**: The problem is stated in an objective, clinical manner. The data are presented as estimates, which is realistic in medical science. The question is a direct application of probability theory and medical knowledge, free from subjective interpretation.\n\n### Step 3: Verdict and Action\nThe problem statement is valid, scientifically sound, and well-posed. A solution can be derived from the provided information.\n\n### Derivation of the Solution\n\nThe problem requires calculating the post-test probability of SSSS given the clinical finding of intact mucosa ($M$). We will use Bayes' theorem. The post-test probability of SSSS, denoted as $P(\\text{SSSS} | M)$, is given by:\n\n$$ P(\\text{SSSS} | M) = \\frac{P(M | \\text{SSSS}) P(\\text{SSSS})}{P(M)} $$\n\nFirst, we calculate the total probability of observing intact mucosa, $P(M)$, using the law of total probability. The two mutually exclusive and exhaustive diagnostic possibilities are SSSS and SJS/TEN.\n\n$$ P(M) = P(M | \\text{SSSS}) P(\\text{SSSS}) + P(M | \\text{SJS/TEN}) P(\\text{SJS/TEN}) $$\n\nUsing the given values:\n- $P(\\text{SSSS}) = 0.40$\n- $P(\\text{SJS/TEN}) = 0.60$\n- $P(M | \\text{SSSS}) = 0.95$\n- $P(M | \\text{SJS/TEN}) = 0.05$\n\nSubstitute these values into the equation for $P(M)$:\n$$ P(M) = (0.95)(0.40) + (0.05)(0.60) $$\n$$ P(M) = 0.38 + 0.03 $$\n$$ P(M) = 0.41 $$\n\nNow, substitute this result back into Bayes' theorem to find $P(\\text{SSSS} | M)$:\n$$ P(\\text{SSSS} | M) = \\frac{P(M | \\text{SSSS}) P(\\text{SSSS})}{P(M)} $$\n$$ P(\\text{SSSS} | M) = \\frac{(0.95)(0.40)}{0.41} $$\n$$ P(\\text{SSSS} | M) = \\frac{0.38}{0.41} $$\n$$ P(\\text{SSSS} | M) \\approx 0.9268 $$\n\nConverting this probability to a percentage gives approximately $92.7\\%$, which is best estimated as $93\\%$.\n\nNext, we evaluate the pathophysiologic explanation provided in each option.\n\n### Option-by-Option Analysis\n\n**A. Approximately $80\\%$; SSSS causes full-thickness epidermal necrosis, but mucosa are relatively resistant, explaining mucosal sparing.**\n- **Probability**: The calculated probability of $80\\%$ is incorrect. Our calculation yields approximately $93\\%$.\n- **Pathophysiology**: This statement is incorrect. Staphylococcal scalded skin syndrome (SSSS) causes a superficial, intraepidermal split at the stratum granulosum. It does **not** cause full-thickness epidermal necrosis. Full-thickness necrosis is the histopathologic hallmark of Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN).\n- **Verdict**: Incorrect.\n\n**B. Approximately $93\\%$; Staphylococcus aureus exfoliative toxin cleaves desmoglein $1$ within the superficial epidermis, sparing mucosa where desmoglein $3$ predominates.**\n- **Probability**: The calculated probability of approximately $93\\%$ is consistent with our derivation ($0.9268$).\n- **Pathophysiology**: This explanation is scientifically correct. The exfoliative toxins (ETA and ETB) produced by *S. aureus* are highly specific proteases that cleave desmoglein-1 (Dsg1), an adhesion protein in desmosomes of the superficial epidermis. This cleavage leads to acantholysis and blistering. Mucous membranes are spared because their epithelial cells express both Dsg1 and desmoglein-3 (Dsg3). The presence of Dsg3 provides compensatory adhesion, so the cleavage of Dsg1 by the toxin is insufficient to cause blistering in mucosal tissues.\n- **Verdict**: Correct.\n\n**C. Approximately $65\\%$; the desquamation in SSSS is due to localized bullous impetigo, which does not affect mucosa.**\n- **Probability**: The calculated probability of $65\\%$ is incorrect.\n- **Pathophysiology**: This statement is incorrect. SSSS is a systemic, toxin-mediated disease where toxins are disseminated hematogenously from a distant site of infection, causing widespread rash. This is distinct from bullous impetigo, where the toxins act locally at the site of a skin infection, causing localized blisters. Conflating SSSS with localized bullous impetigo is a fundamental misunderstanding of the disease process.\n- **Verdict**: Incorrect.\n\n**D. Approximately $99\\%$; SSSS is driven by immune-mediated keratinocyte apoptosis targeting mucosal epithelia less than keratinized epidermis.**\n- **Probability**: The calculated probability of $99\\%$ is incorrect.\n- **Pathophysiology**: This statement incorrectly describes the pathophysiology of SSSS. The mechanism described—widespread, immune-mediated keratinocyte apoptosis—is the driver of SJS/TEN, not SSSS. SSSS is a toxin-mediated disease that causes an epidermal split, not apoptosis.\n- **Verdict**: Incorrect.\n\nBased on the analysis, option B provides both the correct post-test probability and the accurate pathophysiologic explanation.", "answer": "$$\\boxed{B}$$", "id": "5208405"}, {"introduction": "Once a diagnosis of SSSS is strongly suspected, the next step is to initiate appropriate therapy, which requires a firm grasp of the disease's pathophysiology. A frequent point of confusion arises from laboratory results that seem to contradict the clinical picture, such as negative blood cultures in a systemically ill child. This practice [@problem_id:5208363] challenges you to resolve this apparent paradox by focusing on the toxin-mediated nature of SSSS, reinforcing the critical concept that treatment must target the localized source of toxin-producing bacteria, not a non-existent bacteremia.", "problem": "A febrile child presents with diffuse skin tenderness, generalized erythema accentuated in flexures, perioral crusting, and flaccid bullae with a positive Nikolsky sign but no mucosal erosions. The emergency team suspects Staphylococcal Scalded Skin Syndrome (SSSS), obtains blood cultures, and initiates supportive care. By the following day, the blood cultures remain negative. The team is divided on whether to de-escalate antibacterial therapy and how to target empiric antimicrobials. \n\nWhich option best explains why blood cultures are frequently negative in SSSS despite systemic manifestations, and most appropriately guides antimicrobial decisions?\n\nA. The pathogenesis is toxin-mediated: exfoliative toxins produced by a localized Staphylococcus aureus focus disseminate hematogenously and cleave Desmoglein $1$, so bullae and blood are often sterile. Empiric therapy should target Staphylococcus aureus with a beta-lactamase–stable antistaphylococcal beta-lactam (for Methicillin-Sensitive Staphylococcus aureus (MSSA)) or vancomycin if Methicillin-Resistant Staphylococcus aureus (MRSA) risk is high, with consideration of adding clindamycin to suppress toxin production; obtain cultures from suspected primary foci rather than from bullae.\n\nB. Negative blood cultures indicate a viral exanthem; acyclovir should be initiated and antibacterial agents discontinued once viral testing is sent.\n\nC. Bacteremia localizes to the blister cavity, so blood is sterile while bulla fluid is diagnostic; incision and culture of bullae are essential, and broad Gram-negative and anaerobic coverage should be started until culture results return.\n\nD. The systemic features principally reflect a type $4$ hypersensitivity reaction; systemic corticosteroids are first-line, and antibacterial therapy is reserved only for cases with positive blood cultures.\n\nE. Negative blood cultures after $48$ hours rule out a bacterial contribution; discontinue antibacterial therapy and manage with topical agents and emollients alone unless new fevers develop.", "solution": "The user has provided a clinical vignette and a multiple-choice question for which I must provide a detailed analysis. The task requires a rigorous validation of the problem statement before proceeding to a solution.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n\n*   **Patient Profile:** A febrile child.\n*   **Clinical Findings:** Diffuse skin tenderness, generalized erythema accentuated in flexures, perioral crusting, flaccid bullae, positive Nikolsky sign.\n*   **Pertinent Negative:** No mucosal erosions.\n*   **Working Diagnosis:** Staphylococcal Scalded Skin Syndrome (SSSS).\n*   **Initial Management:** Blood cultures obtained, supportive care initiated.\n*   **Laboratory Result:** Blood cultures remain negative by the following day.\n*   **Clinical Question:** The core of the problem is to explain why blood cultures are frequently negative in SSSS and to determine the most appropriate antimicrobial strategy based on this understanding.\n\n**Step 2: Validate Using Extracted Givens**\n\n1.  **Scientific Groundedness:** The problem statement is scientifically sound. The clinical presentation described is a textbook example of Staphylococcal Scalded Skin Syndrome (SSSS). The signs listed (widespread erythema, skin tenderness, flaccid bullae, positive Nikolsky sign) are pathognomonic. The absence of mucosal involvement is a key feature that helps distinguish SSSS from Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN). The underlying pathophysiology involving exfoliative toxins from *Staphylococcus aureus* is well-established in medical science. The question posed—regarding the significance of negative blood cultures and its impact on antibiotic choice—addresses a critical and common point of clinical decision-making in the management of this disease.\n\n2.  **Well-Posedness:** The problem is well-posed. It presents a clear, unambiguous clinical scenario and asks for an explanation of pathophysiology linked directly to a therapeutic decision. A single, best answer can be determined based on established medical principles.\n\n3.  **Objectivity:** The description is entirely objective, using standard clinical terminology. It is free from subjective language or opinion.\n\n4.  **Completeness and Consistency:** The information provided is sufficient to arrive at a definitive answer. The combination of clinical signs and the negative blood culture result are the necessary elements to reason through the options. There are no internal contradictions.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is **valid**. It is scientifically accurate, clinically realistic, well-posed, and objective. I will now proceed with the derivation of the solution and evaluation of the options.\n\n### Solution Derivation\n\nThe problem centers on the pathophysiology of Staphylococcal Scalded Skin Syndrome (SSSS) and its implications for diagnosis and treatment.\n\n**Pathophysiology of SSSS:**\nSSSS is not a direct infection of the skin by bacteria but rather a systemic intoxication. The disease is caused by specific strains of *Staphylococcus aureus* that produce exfoliative toxins (ETs), primarily ETA and ETB. These toxins function as serine proteases. The bacterial infection is typically localized (e.g., nasopharynx, umbilicus, a minor skin abscess, or conjunctivitis) and may not be clinically obvious. From this localized site, the exfoliative toxins are released into the bloodstream and disseminate throughout the body.\n\nThe target of these toxins is a specific protein in the skin: Desmoglein $1$ (Dsg$1$). Dsg$1$ is a key component of desmosomes, which are cellular junctions responsible for holding keratinocytes together. Dsg$1$ is predominantly expressed in the superficial layers of the epidermis, specifically the stratum granulosum. By cleaving Dsg$1$, the toxins disrupt cell-to-cell adhesion, causing intraepidermal splitting. This leads to the characteristic findings of SSSS: widespread erythema, formation of flaccid bullae, and a positive Nikolsky sign (gentle pressure on the skin causes the superficial layer to slough off).\n\n**Implications for Diagnosis and Treatment:**\n*   **Blood Cultures:** Because the systemic illness is caused by the circulating toxin, and not by bacteria in the blood (bacteremia), blood cultures are most often negative. Bacteremia occurs in a small minority of pediatric cases (typically reported as <5%), especially in older children and adults where renal clearance of the toxin is more efficient, but the presence of bacteria is more common. In young children with immature renal function, toxin clearance is poor, leading to high systemic toxin levels without bacteremia.\n*   **Bulla Cultures:** The fluid within the bullae is a result of the epidermal split caused by the toxin. The bacteria are not present at this site. Therefore, cultures of the bulla fluid are characteristically sterile. Culturing these sites is not recommended as it is low-yield and risks introducing a secondary infection.\n*   **Source Cultures:** To identify the causative organism and determine its antibiotic susceptibility, cultures should be obtained from the suspected primary focus of infection (e.g., naopharynx, perineum, conjunctivae, or any purulent lesion).\n*   **Antimicrobial Therapy:** The main goal of treatment is to eradicate the toxin-producing focus of *S. aureus*. This requires systemic antistaphylococcal antibiotics. Empiric therapy must cover *S. aureus*. For Methicillin-Sensitive *S. aureus* (MSSA), a beta-lactamase–stable penicillin (e.g., nafcillin, oxacillin) or a first-generation cephalosporin (e.g., cefazolin) is appropriate. If local epidemiology suggests a high prevalence of Methicillin-Resistant *S. aureus* (MRSA), or if the patient has risk factors for MRSA, vancomycin is the drug of choice. Additionally, clindamycin is often added as an adjunct because it inhibits ribosomal protein synthesis, which can suppress the production of bacterial toxins, including the exfoliative toxins responsible for SSSS. Antibiotic therapy should be initiated promptly based on clinical suspicion and not delayed pending culture results.\n\n### Option-by-Option Analysis\n\n**A. The pathogenesis is toxin-mediated: exfoliative toxins produced by a localized Staphylococcus aureus focus disseminate hematogenously and cleave Desmoglein $1$, so bullae and blood are often sterile. Empiric therapy should target Staphylococcus aureus with a beta-lactamase–stable antistaphylococcal beta-lactam (for Methicillin-Sensitive Staphylococcus aureus (MSSA)) or vancomycin if Methicillin-Resistant Staphylococcus aureus (MRSA) risk is high, with consideration of adding clindamycin to suppress toxin production; obtain cultures from suspected primary foci rather than from bullae.**\nThis option accurately describes the pathophysiology of SSSS: a localized infection with hematogenous dissemination of exfoliative toxins that cleave Desmoglein $1$. It correctly concludes that this mechanism explains why blood and bulla fluid are typically sterile. The recommended antimicrobial strategy is the standard of care: targeting *S. aureus* (with coverage for MSSA and/or MRSA as indicated), considering clindamycin for toxin suppression, and culturing the primary source, not the sterile bullae. Every component of this option is correct.\n**Verdict: Correct**\n\n**B. Negative blood cultures indicate a viral exanthem; acyclovir should be initiated and antibacterial agents discontinued once viral testing is sent.**\nThis is incorrect on multiple fronts. First, the clinical presentation with flaccid bullae and a positive Nikolsky sign is highly specific for SSSS or the more severe SJS/TEN, not a typical viral exanthem. Second, negative blood cultures are the expected finding in SSSS, not evidence against it. Third, initiating acyclovir (an antiviral for herpesviruses) is inappropriate. Finally, discontinuing antibacterial agents would be malpractice, as it would fail to treat the underlying cause and allow the toxin-producing bacteria to proliferate.\n**Verdict: Incorrect**\n\n**C. Bacteremia localizes to the blister cavity, so blood is sterile while bulla fluid is diagnostic; incision and culture of bullae are essential, and broad Gram-negative and anaerobic coverage should be started until culture results return.**\nThis statement fundamentally misunderstands the disease process. There is no \"bacteremia localization\" to the blister. The bulla fluid is sterile because the pathology is toxin-mediated, making the fluid non-diagnostic for bacteria. Incising and culturing bullae is low-yield and contraindicated. The causative agent is *S. aureus*, a Gram-positive coccus; empiric coverage for Gram-negative and anaerobic organisms is unnecessary, poor antimicrobial stewardship, and delays appropriate therapy.\n**Verdict: Incorrect**\n\n**D. The systemic features principally reflect a type $4$ hypersensitivity reaction; systemic corticosteroids are first-line, and antibacterial therapy is reserved only for cases with positive blood cultures.**\nThis is incorrect. SSSS is a direct, enzyme-mediated toxicopathology, not a type $4$ (cell-mediated) hypersensitivity reaction. Systemic corticosteroids are contraindicated in SSSS as they can suppress the immune response needed to clear the infection and have been historically associated with worse outcomes. Withholding antibiotics pending a positive blood culture—an infrequent finding—would dangerously delay essential treatment to eradicate the source of the toxins.\n**Verdict: Incorrect**\n\n**E. Negative blood cultures after $48$ hours rule out a bacterial contribution; discontinue antibacterial therapy and manage with topical agents and emollients alone unless new fevers develop.**\nThis is profoundly incorrect and represents dangerous advice. As established, negative blood cultures are the norm in pediatric SSSS and do not rule out the causative bacterial infection. The bacterial source of the toxin MUST be treated with systemic antibiotics. Discontinuing them based on a negative blood culture would lead to continued toxin production and disease progression. Supportive care (topicals, emollients) is important but is not a substitute for definitive antimicrobial therapy.\n**Verdict: Incorrect**", "answer": "$$\\boxed{A}$$", "id": "5208363"}, {"introduction": "Moving from diagnostic reasoning to therapeutic action, the final step in managing SSSS is the safe and effective administration of antibiotics. This is not merely a theoretical decision but a practical skill requiring precision and careful calculation to prevent under-dosing or toxicity. This hands-on exercise [@problem_id:5208395] provides essential practice in this core clinical competency, guiding you through the step-by-step process of calculating a complete intravenous oxacillin regimen for a pediatric patient, from the dose in milligrams to the final infusion rate in milliliters per hour.", "problem": "A hospitalized child with staphylococcal scalded skin syndrome (SSSS) exhibits diffuse desquamation, fever, and irritability. Staphylococcal scalded skin syndrome is caused by exfoliative toxins from Staphylococcus aureus and is managed with anti-staphylococcal beta-lactams active against methicillin-sensitive Staphylococcus aureus (MSSA). The child weighs $12$ $\\mathrm{kg}$ and has normal renal function. For severe MSSA infections, a widely accepted pediatric dosing fact for oxacillin is a total daily dose of $150$ $\\mathrm{mg/kg/day}$ administered by the intravenous (IV) route, divided every $6$ hours, with a maximum daily dose not to exceed $12$ $\\mathrm{g/day}$.\n\nThe hospital pharmacy reconstitutes oxacillin powder to $100$ $\\mathrm{mg/mL}$ and then dilutes the solution in normal saline to a final infusion concentration of $20$ $\\mathrm{mg/mL}$ to reduce the risk of infusion-site irritation. Standard nursing practice at this institution is to infuse oxacillin over $30$ minutes per dose.\n\nStarting from core definitions and well-tested facts (dose proportional to body mass, division of total daily dose by the number of doses per day, and conversion between mass and volume using solution concentration), and ensuring the maximum daily dose constraint is respected, compute the IV administration schedule for this child by determining:\n- the oxacillin amount per dose in $\\mathrm{mg}$,\n- the volume per dose in $\\mathrm{mL}$ at $20$ $\\mathrm{mg/mL}$,\n- the infusion rate in $\\mathrm{mL/h}$ for a $30$-minute infusion,\n- and the dosing interval in $\\mathrm{hours}$.\n\nExpress the four quantities in the order listed above. No rounding is required; give exact values. For the infusion rate, express the final value in $\\mathrm{mL/h}$.", "solution": "The problem statement is evaluated for validity prior to any attempt at a solution.\n\n### Step 1: Extract Givens\nThe following data and conditions are provided in the problem statement:\n- **Patient Weight ($W$)**: $12 \\ \\mathrm{kg}$\n- **Diagnosis**: Staphylococcal scalded skin syndrome (SSSS)\n- **Pediatric Dosing Guideline for Oxacillin ($D_{guideline}$)**: $150 \\ \\mathrm{mg/kg/day}$ total daily dose, administered intravenously (IV).\n- **Dosing Frequency**: Divided every $6 \\ \\mathrm{hours}$.\n- **Maximum Daily Dose ($D_{max}$)**: Not to exceed $12 \\ \\mathrm{g/day}$.\n- **Final Infusion Concentration ($C_{infusion}$)**: $20 \\ \\mathrm{mg/mL}$.\n- **Infusion Time per Dose ($T_{infusion}$)**: $30 \\ \\mathrm{minutes}$.\n- **Required Computations**:\n    1. Oxacillin amount per dose ($\\mathrm{mg}$)\n    2. Volume per dose ($\\mathrm{mL}$)\n    3. Infusion rate ($\\mathrm{mL/h}$)\n    4. Dosing interval ($\\mathrm{hours}$)\n\n### Step 2: Validate Using Extracted Givens\nThe problem is assessed against the criteria for validity.\n- **Scientific Groundedness**: The problem is scientifically grounded. Staphylococcal scalded skin syndrome is a known pediatric condition caused by exfoliative toxins from *Staphylococcus aureus*. Oxacillin is a standard-of-care antibiotic for methicillin-sensitive *S. aureus* (MSSA) infections. The dosing regimen ($150 \\ \\mathrm{mg/kg/day}$), patient weight, and drug concentrations are all within clinically realistic and medically accepted ranges. The principles of dose calculation based on body weight, division of daily dose, and calculation of infusion rates from volume and time are fundamental to pharmacology and nursing.\n- **Well-Posedness**: The problem is well-posed. It provides all necessary information to compute the four requested quantities. The relationships between mass, volume, concentration, time, and rate are clearly defined. A unique, stable solution can be determined.\n- **Objectivity**: The problem is stated in objective, clinical language, free of ambiguity or subjective claims.\n- **Consistency**: The specified dose must be checked against the maximum daily dose constraint.\n    - Total daily dose: $12 \\ \\mathrm{kg} \\times 150 \\ \\mathrm{mg/kg/day} = 1800 \\ \\mathrm{mg/day}$.\n    - Maximum daily dose: $12 \\ \\mathrm{g/day} = 12000 \\ \\mathrm{mg/day}$.\n    - Since $1800 \\ \\mathrm{mg/day} < 12000 \\ \\mathrm{mg/day}$, the dosing guideline does not contradict the maximum dose constraint.\n- The problem does not exhibit any flaws such as scientific unsoundness, reliance on non-formalizable analogies, missing information, unrealistic conditions, or ambiguity.\n\n### Step 3: Verdict and Action\nThe problem is valid as it is self-contained, scientifically sound, and well-posed. A solution will be derived.\n\n### Solution Derivation\n\nThe solution requires a sequential calculation of the four specified quantities.\n\n**1. Oxacillin amount per dose in $\\mathrm{mg}$**\n\nFirst, the total daily dose for the child is calculated based on their weight and the dosing guideline.\nLet $W$ be the child's weight, and $D_{guideline}$ be the dosing guideline in $\\mathrm{mg/kg/day}$.\nThe total daily dose, $D_{total,daily}$, is given by:\n$$D_{total,daily} = W \\times D_{guideline}$$\nSubstituting the given values:\n$$D_{total,daily} = 12 \\ \\mathrm{kg} \\times 150 \\ \\mathrm{mg/kg/day} = 1800 \\ \\mathrm{mg/day}$$\nThe problem states this total daily dose is divided and administered every $6$ hours. The number of doses per day, $N$, is:\n$$N = \\frac{24 \\ \\mathrm{hours/day}}{6 \\ \\mathrm{hours/dose}} = 4 \\ \\mathrm{doses/day}$$\nThe amount of oxacillin per single dose, $D_{dose}$, is the total daily dose divided by the number of doses per day:\n$$D_{dose} = \\frac{D_{total,daily}}{N} = \\frac{1800 \\ \\mathrm{mg/day}}{4 \\ \\mathrm{doses/day}} = 450 \\ \\mathrm{mg}$$\n\n**2. Volume per dose in $\\mathrm{mL}$**\n\nThe volume of the solution to be administered per dose, $V_{dose}$, is determined by the amount of drug per dose and the final infusion concentration.\nLet $C_{infusion}$ be the final concentration of the oxacillin solution. The relationship between mass (amount), concentration, and volume is $C = \\frac{m}{V}$. Therefore, $V = \\frac{m}{C}$.\nSubstituting the calculated amount per dose and the given concentration:\n$$V_{dose} = \\frac{D_{dose}}{C_{infusion}} = \\frac{450 \\ \\mathrm{mg}}{20 \\ \\mathrm{mg/mL}} = 22.5 \\ \\mathrm{mL}$$\n\n**3. Infusion rate in $\\mathrm{mL/h}$**\n\nThe infusion rate, $R_{infusion}$, is the volume to be infused divided by the duration of the infusion. The problem specifies an infusion time of $30$ minutes. To express the rate in $\\mathrm{mL/h}$, the time must be converted to hours.\nLet $T_{infusion}$ be the infusion time.\n$$T_{infusion} = 30 \\ \\mathrm{min} = 30 \\ \\mathrm{min} \\times \\frac{1 \\ \\mathrm{h}}{60 \\ \\mathrm{min}} = 0.5 \\ \\mathrm{h}$$\nThe infusion rate is then:\n$$R_{infusion} = \\frac{V_{dose}}{T_{infusion}} = \\frac{22.5 \\ \\mathrm{mL}}{0.5 \\ \\mathrm{h}} = 45 \\ \\mathrm{mL/h}$$\n\n**4. Dosing interval in $\\mathrm{hours}$**\n\nThe dosing interval is explicitly stated in the problem as \"divided every $6$ hours.\"\nTherefore, the dosing interval, $\\Delta t$, is:\n$$\\Delta t = 6 \\ \\mathrm{h}$$\n\nThe four computed quantities, in the requested order, are: $450 \\ \\mathrm{mg}$, $22.5 \\ \\mathrm{mL}$, $45 \\ \\mathrm{mL/h}$, and $6 \\ \\mathrm{h}$.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n450 & 22.5 & 45 & 6\n\\end{pmatrix}\n}\n$$", "id": "5208395"}]}